Sanyou Biopharmaceuticals, a Shanghai-based biopharmaceutical company specializing in biologics R&D, signed a strategic cooperation agreement with Medicovestor, Inc., a New York-based biotech company developing first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs). The agreement combines Medicovestor’s ADC platforms—ADoBind, a dimeric antibody architecture, and ADoTope, a bi-epitope targeting system—with Sanyou’s AI-STAL (Artificial Intelligence-enabled Super Trill...